INSIDE: - Medical Device Daily

THURSDAY, MARCH 2, 2006 DIAGNOSTICS &IMAGING WEEK PAGE 13 OF 13P RODUCTB RIEFS• Clinical Data (Newton, Massachusetts), which iscommercializing pharmacogenomics to guide drug utilization,reported that its Vital Diagnostics division has receivedFDA clearance to market a wide-range C-reactive protein(wrCRP) assay, trademarked as the Nanopia wrCRPAssay. The Nanopia wrCRP is an in vitro diagnostic used forthe quantitative measurement of C-reactive protein inserum or plasma. C-reactive protein is a blood componentthat increases rapidly in infections, tissue trauma, surgeryor other injury to the body.• Dade Behring (Deerfield, Illinois) reported that it haslaunched the Cyclosporine Extended Range test for use onits Dimension family of chemistry analyzers and the V-Twinand Viva-E drug testing analyzers. The CyclosporineExtended Range test, or the C2 monitoring test, is a new,more clinically sensitive method used to monitorCyclosporine in transplant patients. It is monitored withintwo hours of patients having ingested the immunosuppressantdrug, which some studies have shown to be a betterpredictor of patient outcome. Dade Behring said itwould continue to offer the original Cyclosporine test. TheP EOPLE IN P LACES• Eastman Kodak (Rochester, New York) has namedtwo vice presidents in health solutions-related units. DavidKiser has been named director and vice president, health,safety and environment, and Anne LeGrand general manager,output systems and mammography solutions inKodak’s Health Group. Kiser joined the company in 1981, andtoday leads Kodak’s global emphasis on sustainability andhealth, safety and environmental stewardship as directorsince 2004. LeGrand joined Kodak in 1999 and assumed hercurrent position in January. She previously worked asregional business general manager, greater Asia region, forcompany said its two Dimension Cyclosporine tests are theonly automated Cyclosporine tests on the market, requiringno manual pretreatment steps.• SenoRx (Aliso Viejo, California), which makes minimallyinvasive devices for the diagnosis and treatment ofbreast cancer, reported that it has made available a new 7-Gauge size probe for its recently launched breast biopsydevice, EnCor. EnCor probes were previously only availablein a 10-gauge size. According to the company, EnCor is thefirst fully programmable, automated, multi-modality, modularbreast biopsy system available, and is the first thatoffers the benefits of both open and closed tissue collection.• Stereotaxis (St. Louis) reported that Central BaptistHospital (Lexington, Kentucky) became the first U.S. centerto treat a patient’s cardiac arrhythmia using the company’spartnered 3-D Localized Ablation Catheter. This diagnosticand ablation catheter recently received FDA approval foruse with the Stereotaxis Niobe Magnetic NavigationSystem. The company said the approval provides StereotaxisNiobe system users in the U.S. with 3-D localizationof the catheter tip, a function that offers physicians preciseand efficient control of the catheter tip with constant feedbackas to the exact location of the catheter in theanatomy.Health Imaging, with responsibility for the business across22 countries. She also was regional business general manager,EAMER for Health Imaging. In October 2005, shebecame general manager, digital output systems, HealthGroup.• L. David Tomei, PhD, co-founder of Xenomics (NewYork), has been appointed CEO of the company. Tomei willremain in his post as co-chairman. He replaces former CEORandy White, PhD, who has left the company to pursueother interests. The company said the appointment ofTomei to the senior management position is the latest stepin its strategic plan to commercialize its Transrenal-DNA(Tr-DNA) technology as a basis to develop a suite of noninvasive,DNA-based diagnostic tests for a range of majordiseases, genetic disorders and other serious healthcareconditions. Tr-DNA can be obtained through urine samples.REPRINTS?For high-quality reprints of articles about your company that have appeared inDiagnostics & Imaging Week, please call Stephen Vance at (404) 262-5511,or e-mail him at stephen.vance@thomson.comTo subscribe, please call DIAGNOSTICS &IMAGING WEEK Customer Service at (800) 688-2421; outside the U.S. and Canada, call (404) 262-5476.Copyright © 2006 Thomson BioWorld ® . Reproduction is strictly prohibited.